Loomis, Sayles & Company
GH icon

Loomis, Sayles & Company’s Guardant Health GH Stock Holding History

Loomis, Sayles & Company’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-124
Closed -$4K – 950
2023
Q2 		$4K Buy
+124
New +$3.56K ﹤0.01% 883
2021
Q2 		– Sell
-80
Closed -$12K – 865
2021
Q1 		$12K Buy
+80
New +$12.1K ﹤0.01% 732

Other funds holding GH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company's GH Position: Q3 2023 in Review

Loomis, Sayles & Company sold out of Guardant Health (GH) in Q3 2023, closing a stake of 124 shares — an estimated $4K sold.

Loomis, Sayles & Company first reported a position in GH in Q1 2021 and held it in 2 quarters. The position peaked at $12K in Q1 2021. 295 funds tracked by Wall St. Rank hold GH as of Q3 2023.

  • Loomis, Sayles & Company reported no remaining Guardant Health position as of Q3 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 124 Guardant Health shares in Q3 2023, an estimated $4K.
  • Loomis, Sayles & Company first reported a position in Guardant Health in Q1 2021 and held it in 2 quarters.
  • Loomis, Sayles & Company's Guardant Health position peaked at $12K in Q1 2021.
  • 295 funds tracked by Wall St. Rank held Guardant Health as of Q3 2023.

Based on Loomis, Sayles & Company's 13F filing for Q3 2023, filed 9 Nov 2023.